Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Turnstone Biologics Corp. (TSBX : NSDQ)

• Company Description    Turnstone Biologics Corp. is a clinical-stage biotechnology company developing new medicines to treat and cure solid tumors by pioneering a differentiated approach to tumor-infiltrating lymphocyte therapy. Turnstone Biologics Corp. is based in SAN DIEGO. Number of Employees: 14

• Price / Volume Information    Yesterday's Closing Price: $0.37 Daily Weekly Monthly 20 Day Moving Average: 450,819 shares Shares Outstanding: 23.14 (millions) Market Capitalization: $8.53 (millions) Beta: 1.35 52 Week High: $2.69 52 Week Low: $0.29 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 3.31% -0.56% 12 Week 11.67% -6.07% Year To Date -25.84% -30.55%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 9310 ATHENA CIRCLE SUITE 300 - LA JOLLA,CA 92037 USA ph: 347-897-5988 fax: - ir@turnstonebio.com https://turnstonebio.com

• General Corporate Information    Officers Sammy Farah - President and Chief Executive Officer Wendy Worcester - Vice President Jerel Davis - Director Robert Gould - Director Rishi Gupta - Director Peer Information Turnstone Biologics Corp. (CORR.) Turnstone Biologics Corp. (RSPI) Turnstone Biologics Corp. (CGXP) Turnstone Biologics Corp. (BGEN) Turnstone Biologics Corp. (GTBP) Turnstone Biologics Corp. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 90042W100 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/13/25 Share - Related Items Shares Outstanding: 23.14 Most Recent Split Date: (:1) Beta: 1.35 Market Capitalization: $8.53 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.14 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.69 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/13/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.43 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 40.00% vs. Previous Quarter: 8.93% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -162.79 12/31/24 - -131.88 ROA 06/30/25 - - 03/31/25 - -124.10 12/31/24 - -104.99 Current Ratio 06/30/25 - - 03/31/25 - 3.70 12/31/24 - 4.17 Quick Ratio 06/30/25 - - 03/31/25 - 3.70 12/31/24 - 4.17 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 0.86 12/31/24 - 1.36 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©